OSSDSIGN AB |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.98 SEK | -3.44% |
|
-9.55% | +12.50% |
| May. 14 | Transcript : OssDsign AB, Q1 2024 Earnings Call, May 14, 2024 | |
| May. 14 | OssDsign AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- Based on current prices, the company has particularly high valuation levels.
- The company appears highly valued given the size of its balance sheet.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Sector: Medical Equipment, Supplies & Distribution
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +12.50% | 84.87M | - | ||
| +11.57% | 127B | A- | ||
| -4.98% | 11.32B | A- | ||
| +3.22% | 9.04B | C | ||
| +38.90% | 5.56B | B+ | ||
| -21.83% | 4.72B | C | ||
| +8.74% | 3.45B | C- | ||
| -6.82% | 2.86B | B- | ||
| -6.99% | 2.07B | - | ||
| -13.32% | 2.04B | - | - |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
-
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- OSSD Stock
- Ratings OssDsign AB
